Perceptive Advisors Increases Stake in MeiraGTx and Sees Warrant Terms Adjusted Amidst Positive Developments

summarizeSummary

Perceptive Advisors, a significant institutional investor, increased its ownership in MeiraGTx by purchasing $5 million in a recent offering and saw the exercise price of its warrants adjusted to $8.00 per share, signaling continued investment amidst positive company developments.

check_boxKey Events

• Increased Ownership

  Perceptive Life Sciences Master Fund, Ltd. purchased 555,555 ordinary shares for $5 million at $9.00 per share in MeiraGTx's underwritten offering on April 17, 2026.

• Warrant Terms Adjusted

  The exercise price for 700,000 warrants held by Perceptive was adjusted to $8.00 per share on March 25, 2026, making them more in-the-money and increasing their potential value.

• Significant Stake Maintained

  Perceptive Advisors and its affiliates now collectively own 11,742,117 ordinary shares, representing 12.6% of the company's outstanding shares.

• Context of Recent Positive News

  This increased investment follows MeiraGTx's recent announcements of positive clinical data, reacquisition of bota-vec rights, and a strategic collaboration with Hologen, indicating strong investor confidence.

auto_awesomeAnalysis

This Schedule 13D/A reveals Perceptive Advisors' continued strong commitment to MeiraGTx, highlighted by a $5 million share purchase in the recent underwritten offering. The adjustment of warrant exercise prices to $8.00 per share significantly enhances the value of Perceptive's derivative holdings and increases the likelihood of future exercise, potentially providing additional capital to the company. This active participation and favorable warrant adjustment occur amidst a series of highly positive developments for MeiraGTx, including promising clinical data, the reacquisition of a key gene therapy program, and a substantial upfront payment from a new collaboration. Perceptive's actions suggest confidence in the company's strategic direction and future prospects.